Top Markets
#1 NEW X CEO IS BACK NEW X CEO IS BACK +210,975.57%
#2 Beta Finance Beta Finance +8,979.03%
#3 Tribe Tribe +73.83%
#4 Orochi Network Orochi Network +53.40%
#5 Chainbase Chainbase +40.85%
#6 BabyBoomToken BabyBoomToken +34.25%
#7 Block Street Block Street +31.59%
#8 Chrema Coin Chrema Coin +28.62%
#9 Freysa AI Freysa AI +26.78%
#10 B3 (Base) B3 (Base) +25.98%
Coin of the day
NEW X CEO IS BACK NEW X CEO IS BACK
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rang in aandelen #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Aandeelprijs
$0.00244926
Marktkapitalisatie
$51.67K
Verandering (1 dag)
5.88%
Verandering (1 jaar)
110.15%
Land
GB
Handel Nuformix plc (NFX)

Categorie

Healthcare
P/S-ratio voor Nuformix plc (NFX)
P/S-ratio op March 2026 TTM: 0.00
Volgens de meest recente financiële rapporten en aandelenkoers van Nuformix plc is de huidige P/S-ratio (TTM) 0.00. Eind 2024 had het bedrijf een P/S-ratio van 0.00.
P/S-ratiohistoriek voor Nuformix plc van 2014 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 -100.00%
2022 116.70 74.68%
2021 66.81 87.30%
2020 35.67 81.62%
2019 19.64 -95.96%
2018 485.61 0.00%
2017 0.00 -100.00%
2016 2.23 0.00%
2014 0.00 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
3.55 -
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.90 -
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.40 -
US
UCB SA UCB SA
UCB SA
UCB.BR
6.14 -
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.04 -
AU